AUS-001 overcomes drug resistance with reversible effects on peripheral neuropathy in models of GBM
June 3, 2024
Researchers from Australis Pharmaceuticals Pty Ltd. have presented preclinical data for the microtubule-destabilizing agent AUS-001, which is being evaluated in models of glioblastoma (GBM).
